Prime Medicine (PRME) Accumulated Depreciation & Amortization (2021 - 2026)

Prime Medicine (PRME) has 6 years of Accumulated Depreciation & Amortization data on file, last reported at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation & Amortization rose 9.18% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 9.18% YoY), and the FY2025 full-year result was $7.3 million, up 19.47% from the prior year.
• Accumulated Depreciation & Amortization for Q1 2026 stood at $1.9 million, down from $7.3 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $7.3 million in Q4 2025 and bottomed at $293000.0 in Q1 2022.
• The 5-year median for Accumulated Depreciation & Amortization is $1.7 million (2025), against an average of $2.5 million.
• The widest annual swing landed in 2022, when Accumulated Depreciation & Amortization surged 299.41%; it then sank 54.26% in 2024.
• A 5-year view of Accumulated Depreciation & Amortization shows it stood at $2.2 million in 2022, then jumped by 109.22% to $4.7 million in 2023, then soared by 31.7% to $6.1 million in 2024, then gained by 19.47% to $7.3 million in 2025, then sank by 74.65% to $1.9 million in 2026.
• The last three Accumulated Depreciation & Amortization figures came in at $1.9 million (Q1 2026), $7.3 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.

Peer Comparison